160 related articles for article (PubMed ID: 35654466)
1.
Coulson AB; Royle KL; Pawlyn C; Cairns DA; Hockaday A; Bird J; Bowcock S; Kaiser M; de Tute R; Rabin N; Boyd K; Jones J; Parrish C; Gardner H; Meads D; Dawkins B; Olivier C; Henderson R; Best P; Owen R; Jenner M; Kishore B; Drayson M; Jackson G; Cook G
BMJ Open; 2022 Jun; 12(6):e056147. PubMed ID: 35654466
[TBL] [Abstract][Full Text] [Related]
2. Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trial.
Royle KL; Coulson AB; Ramasamy K; Cairns DA; Hockaday A; Quezada S; Drayson M; Kaiser M; Owen R; Auner HW; Cook G; Meads D; Olivier C; Barnard L; Lambkin R; Paterson A; Dawkins B; Chapman M; Pratt G; Popat R; Jackson G; Bygrave C; Sive J; de Tute R; Chantry A; Parrish C; Cook M; Asher S; Yong K
BMJ Open; 2022 Nov; 12(11):e063037. PubMed ID: 36396306
[TBL] [Abstract][Full Text] [Related]
3. The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial.
Striha A; Ashcroft AJ; Hockaday A; Cairns DA; Boardman K; Jacques G; Williams C; Snowden JA; Garg M; Cavenagh J; Yong K; Drayson MT; Owen R; Cook M; Cook G
Trials; 2018 Mar; 19(1):169. PubMed ID: 29514706
[TBL] [Abstract][Full Text] [Related]
4. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.
Kumar SK; Jacobus SJ; Cohen AD; Weiss M; Callander N; Singh AK; Parker TL; Menter A; Yang X; Parsons B; Kumar P; Kapoor P; Rosenberg A; Zonder JA; Faber E; Lonial S; Anderson KC; Richardson PG; Orlowski RZ; Wagner LI; Rajkumar SV
Lancet Oncol; 2020 Oct; 21(10):1317-1330. PubMed ID: 32866432
[TBL] [Abstract][Full Text] [Related]
5. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.
Jackson GH; Davies FE; Pawlyn C; Cairns DA; Striha A; Collett C; Hockaday A; Jones JR; Kishore B; Garg M; Williams CD; Karunanithi K; Lindsay J; Jenner MW; Cook G; Russell NH; Kaiser MF; Drayson MT; Owen RG; Gregory WM; Morgan GJ;
Lancet Oncol; 2019 Jan; 20(1):57-73. PubMed ID: 30559051
[TBL] [Abstract][Full Text] [Related]
6. The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor.
Hinsley S; Walker K; Sherratt D; Bailey L; Reed S; Flanagan L; McKee S; Brudenell Straw F; Dawkins B; Meads D; Auner HW; Kaiser MF; Cook M; Brown S; Cook G;
Trials; 2020 Oct; 21(1):826. PubMed ID: 33008427
[TBL] [Abstract][Full Text] [Related]
7. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
8. Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial.
Mina R; Musto P; Rota-Scalabrini D; Paris L; Gamberi B; Palmas A; Aquino S; de Fabritiis P; Giuliani N; De Rosa L; Gozzetti A; Cellini C; Bertamini L; Capra A; Oddolo D; Vincelli ID; Ronconi S; Pavone V; Pescosta N; Cea M; Fioritoni F; Ballanti S; Grasso M; Zamagni E; Belotti A; Boccadoro M; Gay F
Lancet Oncol; 2023 Jan; 24(1):64-76. PubMed ID: 36528035
[TBL] [Abstract][Full Text] [Related]
9. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
Gay F; Musto P; Rota-Scalabrini D; Bertamini L; Belotti A; Galli M; Offidani M; Zamagni E; Ledda A; Grasso M; Ballanti S; Spadano A; Cea M; Patriarca F; D'Agostino M; Capra A; Giuliani N; de Fabritiis P; Aquino S; Palmas A; Gamberi B; Zambello R; Petrucci MT; Corradini P; Cavo M; Boccadoro M
Lancet Oncol; 2021 Dec; 22(12):1705-1720. PubMed ID: 34774221
[TBL] [Abstract][Full Text] [Related]
10. Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma.
Salwender H; Bertsch U; Weisel K; Duerig J; Kunz C; Benner A; Blau IW; Raab MS; Hillengass J; Hose D; Huhn S; Hundemer M; Andrulis M; Jauch A; Seidel-Glaetzer A; Lindemann HW; Hensel M; Fronhoffs S; Martens U; Hansen T; Wattad M; Graeven U; Munder M; Fenk R; Haenel M; Scheid C; Goldschmidt H
BMC Cancer; 2019 May; 19(1):504. PubMed ID: 31138244
[TBL] [Abstract][Full Text] [Related]
11. Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.
Jackson GH; Davies FE; Pawlyn C; Cairns DA; Striha A; Collett C; Waterhouse A; Jones JR; Kishore B; Garg M; Williams CD; Karunanithi K; Lindsay J; Wilson JN; Jenner MW; Cook G; Kaiser MF; Drayson MT; Owen RG; Russell NH; Gregory WM; Morgan GJ;
Lancet Haematol; 2019 Dec; 6(12):e616-e629. PubMed ID: 31624047
[TBL] [Abstract][Full Text] [Related]
12. Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial.
Jackson GH; Pawlyn C; Cairns DA; de Tute RM; Hockaday A; Collett C; Jones JR; Kishore B; Garg M; Williams CD; Karunanithi K; Lindsay J; Rocci A; Snowden JA; Jenner MW; Cook G; Russell NH; Drayson MT; Gregory WM; Kaiser MF; Owen RG; Davies FE; Morgan GJ;
PLoS Med; 2021 Jan; 18(1):e1003454. PubMed ID: 33428632
[TBL] [Abstract][Full Text] [Related]
13. Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial.
Dytfeld D; Wróbel T; Jamroziak K; Kubicki T; Robak P; Walter-Croneck A; Czyż J; Tyczyńska A; Druzd-Sitek A; Giannopoulos K; Nowicki A; Szczepaniak T; Łojko-Dankowska A; Matuszak M; Gil L; Puła B; Rybka J; Majcherek M; Usnarska-Zubkiewicz L; Szukalski Ł; Końska A; Zaucha JM; Walewski J; Mikulski D; Czabak O; Robak T; Lahoud OB; Zonder JA; Griffith K; Stefka A; Major A; Derman BA; Jakubowiak AJ
Lancet Oncol; 2023 Feb; 24(2):139-150. PubMed ID: 36642080
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
15. Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial.
Mai EK; Goldschmid H; Miah K; Bertsch U; Besemer B; Hänel M; Krzykalla J; Fenk R; Schlenzka J; Munder M; Dürig J; Blau IW; Huhn S; Hose D; Jauch A; Kunz C; Mann C; Weinhold N; Scheid C; Schroers R; von Metzler I; Schieferdecker A; Thomalla J; Reimer P; Mahlberg R; Graeven U; Kremers S; Martens UM; Kunz C; Hensel M; Benner A; Seidel-Glätzer A; Weisel KC; Raab MS; Salwender HJ;
Lancet Haematol; 2024 Feb; 11(2):e101-e113. PubMed ID: 38302221
[TBL] [Abstract][Full Text] [Related]
16. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial.
Facon T; Kumar SK; Plesner T; Orlowski RZ; Moreau P; Bahlis N; Basu S; Nahi H; Hulin C; Quach H; Goldschmidt H; O'Dwyer M; Perrot A; Venner CP; Weisel K; Mace JR; Raje N; Tiab M; Macro M; Frenzel L; Leleu X; Ahmadi T; Wang J; Van Rampelbergh R; Uhlar CM; Tromp B; Delioukina M; Vermeulen J; Usmani SZ
Lancet Oncol; 2021 Nov; 22(11):1582-1596. PubMed ID: 34655533
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
Durie BGM; Hoering A; Abidi MH; Rajkumar SV; Epstein J; Kahanic SP; Thakuri M; Reu F; Reynolds CM; Sexton R; Orlowski RZ; Barlogie B; Dispenzieri A
Lancet; 2017 Feb; 389(10068):519-527. PubMed ID: 28017406
[TBL] [Abstract][Full Text] [Related]
18. Frailty impairs the feasibility of induction therapy but not of maintenance therapy in elderly myeloma patients: final results of the German Maintenance Study (GERMAIN).
Brioli A; Manz K; Pfirrmann M; Hänel M; Schwarzer AC; Prange-Krex G; Fabisch C; Knop S; Illmer T; Krammer-Steiner B; Hochhaus A; von Lilienfeld-Toal M; Mügge LO
J Cancer Res Clin Oncol; 2020 Mar; 146(3):749-759. PubMed ID: 31788741
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.
Manasanch EE; Shah JJ; Lee HC; Weber DM; Thomas SK; Amini B; Feng L; Berkova Z; Hildebrandt M; Orlowski RZ
Lancet Haematol; 2018 Dec; 5(12):e628-e640. PubMed ID: 30501870
[TBL] [Abstract][Full Text] [Related]
20. Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial.
Bringhen S; D'Agostino M; Paris L; Ballanti S; Pescosta N; Spada S; Pezzatti S; Grasso M; Rota-Scalabrini D; De Rosa L; Pavone V; Gazzera G; Aquino S; Poggiu M; Santoro A; Gentile M; Baldini L; Petrucci MT; Tosi P; Marasca R; Cellini C; Palumbo A; Falco P; Hájek R; Boccadoro M; Larocca A
Haematologica; 2020 Jul; 105(7):1937-1947. PubMed ID: 31582542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
